Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. Alonso López S, et al. Among authors: olveira a. Hepatology. 2020 Dec;72(6):1924-1934. doi: 10.1002/hep.31588. Epub 2020 Nov 10. Hepatology. 2020. PMID: 33022803
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Among authors: olveira a. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Zeuzem S, et al. Among authors: olveira a. J Hepatol. 2016 Feb;64(2):292-300. doi: 10.1016/j.jhep.2015.09.024. Epub 2015 Oct 8. J Hepatol. 2016. PMID: 26453968 Clinical Trial.
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Alonso S, et al. Among authors: olveira a. J Viral Hepat. 2017 Apr;24(4):304-311. doi: 10.1111/jvh.12648. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935168 Free article.
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA. Puigvehí M, et al. Among authors: olveira a. Liver Int. 2019 Jan;39(1):90-97. doi: 10.1111/liv.13950. Epub 2018 Nov 12. Liver Int. 2019. PMID: 30160363
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1.
Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. Berenguer J, et al. Among authors: olveira a. Open Forum Infect Dis. 2019 May 7;6(5):ofz214. doi: 10.1093/ofid/ofz214. eCollection 2019 May. Open Forum Infect Dis. 2019. PMID: 31139679 Free PMC article.
Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
Abadía M, Montes ML, Ponce D, Froilán C, Romero M, Poza J, Hernández T, Fernández-Martos R, Olveira A; “La Paz Portal Hypertension” Study Group Investigators. Abadía M, et al. Among authors: olveira a. World J Gastroenterol. 2019 Jun 7;25(21):2665-2674. doi: 10.3748/wjg.v25.i21.2665. World J Gastroenterol. 2019. PMID: 31210717 Free PMC article.
68 results